Daily Bulletin

Men's Weekly

.

The Oxford/AstraZeneca vaccine is the first to publish peer-reviewed efficacy results. Here's what they tell us — and what they don't

  • Written by Kirsty Wilson, Postdoctoral Research Fellow, RMIT University
The Oxford/AstraZeneca vaccine is the first to publish peer-reviewed efficacy results. Here's what they tell us — and what they don'tShutterstock

The Oxford/AstraZeneca vaccine this week became the first major COVID vaccine candidate to have efficacy results from phase 3 trials published in a peer-reviewed journal.

The vaccine, AZD1222, is a viral vector vaccine. Researchers took an adenovirus from chimpanzees and modified it with the aim of training the immune system to mount a...

Read more: The Oxford/AstraZeneca vaccine is the first to publish peer-reviewed efficacy results. Here's what...

Business News

Promotional Badges: A New Avenue for Marketing in the Digital Age

Social media campaigns, digital ads, and influencer partnerships dominate today’s marketing industry. However, promotional products are making a comeback as brands look for unique and creative ways ...

Daily Bulletin - avatar Daily Bulletin

Why Content Marketing Is Critical for Your Business’s Success?

On some level, content marketing is used in every digital marketing campaign. Important messaging about a product, service, or brand will be conveyed through content marketing assets, whether writte...

Daily Bulletin - avatar Daily Bulletin

Tips from Organisational Change Management Experts for Leading Successful Transitions

Corporate evolution has accelerated dramatically in today's volatile business environment, requiring leaders to develop sophisticated approaches to managing workforce transitions across technologica...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals